Evidence map›Paper›PMID 30986014›Full record

ArticleThe American journal of managed care2019

Time to fecal immunochemical test completion for colorectal cancer screening.

Cameron B Haas, Amanda I Phipps, Anjum Hajat, Jessica Chubak, Karen J Wernli

Abstract read
In one paragraph

Article in The American journal of managed care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Video brochures in a mailed fecal immunochemical test outreach program provide cancer screening information in a user-friendly format for rural Appalachian community members.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2024
    Trial
  3. Trial
  4. Trial
  5. Observational
  6. Article
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cameron B HaasKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Ste 1600, Seattle, WA 98101. Email: haas.c@ghc.org.
Amanda I Phipps
Anjum Hajat
Jessica Chubak
Karen J Wernli

Funding

XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Nicole Ann Errett · 1995 to 2026
$42.5M
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)U54CA163261 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHUBAK, JESSICA · 2011 to 2017
$7.3M
Contributing Factors and Consequences of Cancer Health DisparitiesT32CA094880 · NCI · UNIVERSITY OF WASHINGTON · PI Christopher I Li, AMANDA IRENE PHIPPS · 2017 to 2026
$3.7M
NCI NIH HHS T32 CA094880NCI NIH HHS U54 CA163261NIEHS NIH HHS P30 ES007033
6 · The paper itself

Abstract

objectivesFecal immunochemical tests (FITs) can efficiently screen for colorectal cancer (CRC), but little is known on the timing to their completion. We investigate the time to return of a FIT following an order and describe patient characteristics associated with FIT return. STUDY

designRetrospective cohort study.

methodsWe identified 63,478 members of Kaiser Permanente Washington, aged 50 to 74 years, who received a FIT order from 2011 through 2012. Patient characteristics were ascertained through administrative and electronic health record data sources. We compared time from FIT order to return by patient characteristics using Kaplan-Meier and Cox regression methods.

resultsAbout half (53.7%) of members completed a FIT. Median time from order to return was 13 days (mean, 44.5 days; interquartile range, 6-42 days). There was higher completion of FITs among Asian patients (hazard ratio [HR], 1.43; 95% CI, 1.38-1.48), black patients (HR, 1.13; 95% CI, 1.08-1.19), and Hispanic patients (HR, 1.10; 95% CI, 1.04-1.16) compared with white patients; among patients with recent CRC testing (vs no testing in past 2 years; HR, 1.90; 95% CI, 1.86-1.95); and among patients with Medicare insurance (vs commercial; HR, 1.30; 95% CI, 1.24-1.37). Factors associated with decreased FIT completion included younger age (50-54 years vs 70-74 years; HR, 0.87; 95% CI, 0.82-0.92), obesity (vs normal body mass index; HR, 0.88; 95% CI, 0.86-0.91), and higher Charlson Comorbidity Index score (≥3 vs 0; HR, 0.82; 95% CI, 0.79-0.87).

conclusionsTime to return of FIT varies by patient characteristics. We observed greater FIT completion among people of color, suggesting that racial disparities in CRC may not be due to patient completion of the test after an order is received.

Indexed as

Occult BloodAgedAge FactorsColorectal NeoplasmsComorbidityEarly Detection of CancerFemaleHumansImmunohistochemistryInsurance, HealthKaplan-Meier EstimateMaleMiddle AgedRacial GroupsRegression AnalysisRetrospective Studies

Identifiers

PMID30986014
PMCPMC7170013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.